Stifel initiated coverage of Abeona Therapeutics with a Buy rating and $21 price target. Prademagene zamikeracel, or pz-cel, are genetically engineered autlogous epidermal sheets to treat large wounds in recessive epidermolysis bullosa, or RDEB, notes the analyst, who has “optimism” regarding the commercial opportunity in DEB, wounds in RDEB that are likely to necessitate a complementary approach to Vyjuvek that pz-cel can address, and feedback from doctors and payors that support the feasibility of a “polypharmacy approach” if pz-cel is approved.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
- Abeona Therapeutics price target lowered to $21 from $28 at Cantor Fitzgerald
- Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
- Abeona Therapeutics reports Q1 EPS ($1.16), consensus (51c)
- ABEO Upcoming Earnings Report: What to Expect?